Full access
Professional News
Published Online: 15 June 2012

Medication Coupled With Rewards Found to Reduce Cannabis Use

Aaron LevinAuthors Info & Affiliations
Publication: Psychiatric News
Volume 47, Number 12
https://doi.org/10.1176/pn.47.12.psychnews_47_12_5-b

Abstract

Doubling up a system of rewards with medication produces encouraging results and opens the door to further research.
Researchers have been looking for effective ways to treat cannabis use in young people. A study by the National Institute on Drug Abuse (NIDA) found that 23 percent of high school seniors said that they had ever used marijuana, and 7 percent acknowledged using it daily.
Kevin Gray, M.D., is testing the combination of n-acetylcysteine with contingency management as a means of increasing abstinence rates among adolescent cannabis users.
David Hathcox
“Rates of initiation are increasing, possibly due to decreasing perceptions of risk due to the medical-marijuana movement,” said Kevin Gray, M.D., an associate professor of psychiatry and behavioral sciences at the Medical University of South Carolina.
“We have evidence-based psychosocial treatments of substance use disorders, but they have only modest efficacy,” said Gray at APA’s 2012 annual meeting in Philadelphia in May. Studies of medications like buspirone, dronabinol, gabapentin, and lofexidine have produced mixed results when used alone, but better outcomes when used along with psychosocial therapies.
Gray recently tested a combination of a drug with contingency management, in which patients are rewarded for good behavior such as meeting appointments or producing clean urine tests. The drug used was n-acetylcysteine (NAC), which is approved as a mucolytic agent and for treating acetaminophen overdoses. It is also sold over the counter as a dietary supplement for its alleged “antioxidant and liver-protecting effects.”
NAC activates the cysteine-glutamate exchanger in the nucleus accumbens, re-equalizes glutamate, and has known behavioral effects, explained Gray.
The 116 randomized study participants received either 1,200 mg twice a day of NAC or a placebo.
Contingency management offers an escalating set of monetary payments to participants, with payments dropping back to baseline if they miss a visit or have a positive urine test. All participants received brief weekly counseling as well.
Using pill counts, the researchers found a 95 percent adherence rate among those taking NAC and 93 percent among placebo users. Intention-to-treat response, including dropouts, showed an end-of-treatment abstinence rate of 41 percent among those taking NAC, compared with 27 percent for the placebo subjects.
These findings are intriguing but not conclusive, cautioned Gray. For one thing, he was testing two interventions at the same time, raising but not answering several other questions—for example, “Does NAC treatment require contingency management to work? How would a change in dosage affect results? Can it be used with other substance disorders? How will it work in adults?”
A full report on this clinical trial appears in AJP in Advance, posted at http://ajp.psychiatryonline.org/AJPInAdvance.aspx.

Information & Authors

Information

Published In

Go to Psychiatric News
Psychiatric News
Volume 47 • Number 12 • June 15, 2012
Pages: 5b

History

Published online: 15 June 2012
Published in print: June 15, 2012

Authors

Affiliations

Metrics & Citations

Metrics

Citations

Export Citations

If you have the appropriate software installed, you can download article citation data to the citation manager of your choice. Simply select your manager software from the list below and click Download.

For more information or tips please see 'Downloading to a citation manager' in the Help menu.

Format
Citation style
Style
Copy to clipboard
Tips for downloading citations

There are no citations for this item

View Options

View options

Get Access

Login options

Already a subscriber? Access your subscription through your login credentials or your institution for full access to this article.

Personal login Institutional Login Open Athens login

Not a subscriber?

Subscribe Now / Learn More

PsychiatryOnline subscription options offer access to the DSM-5-TR® library, books, journals, CME, and patient resources. This all-in-one virtual library provides psychiatrists and mental health professionals with key resources for diagnosis, treatment, research, and professional development.

Need more help? PsychiatryOnline Customer Service may be reached by emailing [email protected] or by calling 800-368-5777 (in the U.S.) or 703-907-7322 (outside the U.S.).

Media

Figures

Other

Tables

Share

Share

Share article link

Share

×

As described within the American Psychiatric Association (APA)'s Privacy Policy and Terms of Use, this website utilizes cookies, including for the purpose of offering an optimal online experience and services tailored to your preferences. Please read the entire Privacy Policy and Terms of Use. By closing this message, browsing this website, continuing the navigation, or otherwise continuing to use the APA's websites, you confirm that you understand and accept the terms of the Privacy Policy and Terms of Use, including the utilization of cookies.